

Favipiravir-induced inflammatory and hydropic degenerative liver injury in rats

Sami Bilici^{1,D,F}, Durdu Altuner^{2,C}, Zeynep Suleyman^{3,C}, Seval Bulut^{3,C}, Cengiz Sarigul^{4,B,C}, Mine Gulaboglu^{5,B,C}, Fikret Altindag^{6,A,C}, Adalet Ozcicek^{7,E}, Cebrail Gursul^{8,E}, Halis Suleyman^{2,D,F}

¹ Department of General Surgery, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

² Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

³ Department of Pharmacology, Institute of Health Sciences, Erzincan Binali Yıldırım University, Turkey

⁴ Department of Medical Biochemistry, Faculty of Medicine, Atatürk University, Erzurum, Turkey

⁵ Department of Biochemistry, Faculty of Pharmacy, Atatürk University, Erzurum, Turkey

⁶ Department of Histology and Embryology, Faculty of Medicine, Van Yüzüncü Yıl University, Turkey

⁷ Department of Internal Medicine, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

⁸ Department of Physiology, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;

D – writing the article; E – critical revision of the article; F – final approval of the article

Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online)

Adv Clin Exp Med. 2023;32(8):881–887

Address for correspondence

Halis Suleyman

E-mail: halis.suleyman@gmail.com

Funding sources

None declared

Conflict of interest

None declared

Received on October 19, 2022

Reviewed on November 16, 2022

Accepted on January 8, 2023

Published online on February 8, 2023

Cite as

Bilici S, Altuner D, Suleyman Z, et al. Favipiravir-induced inflammatory and hydropic degenerative liver injury in rats.

Adv Clin Exp Med. 2023;32(8):881–887.

doi:10.17219/acem/159089

DOI

10.17219/acem/159089

Copyright

Copyright by Author(s)

This is an article distributed under the terms of the

Creative Commons Attribution 3.0 Unported (CC BY 3.0)

(https://creativecommons.org/licenses/by/3.0/)

Abstract

Background. Favipiravir is very effective in the treatment of many viral infections, especially at high doses. It was used at such doses to treat coronavirus disease 2019 (COVID-19) during the pandemic. However, liver damage was reported in patients undergoing such treatment.

Objectives. This study aimed to investigate the effects of low and high doses of favipiravir on the liver of rats, using biochemical and histopathological methods.

Materials and methods. Wistar albino rats were allocated to one of 3 groups, namely a healthy group (HG), a 100 mg/kg favipiravir (FAV-100) group and a 400 mg/kg favipiravir (FAV-400) group. Favipiravir was administered orally at 100 mg/kg and 400 mg/kg doses to the FAV-100 (n = 6) and FAV-400 (n = 6) groups, respectively. Distilled water was administered orally (1 mL) using the same method to the HG (n = 6). This procedure was repeated twice a day for 1 week. At the end of this period, the animals were euthanized with a high dose of thiopental anesthesia (50 mg/kg) and their liver tissues were removed.

Results. Favipiravir caused an increase in malondialdehyde (MDA), nuclear factor kappa B (NF-κB) and interleukin 6 (IL-6) levels in the liver tissue, as well as elevated alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) levels in the blood. Moreover, favipiravir caused a decrease in total glutathione (tGSH), superoxide dismutase (SOD) and catalase (CAT) levels. In addition, severe edema, lymphocyte infiltration and hydropic degeneration were observed in the liver tissue of the FAV-400.

Conclusions. High-dose favipiravir caused more significant oxidative and inflammatory damage in the liver tissue of rats than low-dose favipiravir.

Key words: inflammation, rat, hydropic degeneration, favipiravir

Background

Favipiravir is an antiviral drug that has been tested for use against coronavirus disease 2019 (COVID-19).¹ It has also been found to be effective in treating influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).² Favipiravir is effective against RNA viruses such as human rhinovirus, respiratory syncytial virus, metapneumovirus, and parainfluenza, and has been considered a candidate for the treatment of hantavirus-induced infections.³ The drug is converted to the active favipiravir-ribofuranosyl-50-triphosphate metabolite through phosphorylation and ribosylation in tissues.⁴ The antiviral effects of favipiravir depend on blocking the inward and outward movements of viruses by the drug.⁵ The action is achieved through the inhibition of RNA-dependent RNA polymerase (RdRp).⁶ Favipiravir has been found to be effective against these infections at high doses.⁷ Two doses of 2400–3000 mg every 12 h have been recommended for the treatment of COVID-19, followed by 1200–1800 mg every 12 h.^{8,9} However, favipiravir can cause toxic effects at high doses.¹⁰

The most frequent toxic effects of favipiravir are diarrhea, nephrotoxicity, increased serum uric acid and transaminase levels, decreased white blood cell count and neutrophil level, nausea, vomiting, abdominal pain, skin rash, itching, delirium, hallucinations, and convulsions.^{11,12} Moreover, liver damage has been reported in patients undergoing favipiravir treatment.¹³ This was also shown experimentally, with favipiravir causing hepatic dysfunction and vacuolization in hepatocytes.^{13,14} Furthermore, favipiravir treatment was shown to cause an increase in liver enzymes and oxidative and histopathological damage in rats. Recent study reported that endogenous oxidants and antioxidants such as superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), and total glutathione (tGSH) played a critical role in the pathogenesis of favipiravir hepatotoxicity.¹⁵ These data indicated that oxidative stress was responsible for favipiravir-induced hepatotoxicity. However, no studies investigated the effects of favipiravir on the liver of animals treated with low and high doses of this drug.

Objectives

The purpose of the study was to examine the biochemical and histopathological effects of different doses of favipiravir on rat liver.

Materials and methods

Animals

Rats were obtained from Medical Experimental Application and Research Center (Erzincan Binali Yıldırım

University, Erzincan, Turkey). In total, 18 albino male Wistar rats weighing 280–290 g were included in the study. Before the commencement of the study, the rats were housed at room temperature (22°C) in a 12-hour light/dark cycle. The animals were fed with normal tap water and pellet food. The procedures were approved by the Animal Experiments Local Ethics Committee (September 29, 2022, meeting No. 09/46, approval No. E-85748827-050.01.04-204261)

Chemicals

The thiopental sodium was procured from a commercial supplier (IE Ulagay, Istanbul, Turkey), and the favipiravir was obtained from the Education and Research Hospital (Erzincan, Turkey) affiliated with the Ministry of Health.

Animal groups

The rats were randomly assigned to one of 3 groups ($n = 6/\text{group}$), namely a healthy group (HG), a 100 mg/kg favipiravir (FAV-100) group and a 400 mg/kg favipiravir (FAV-400) group.

Experimental procedure

Favipiravir was given orally at doses of 100 mg/kg or 400 mg/kg to the FAV-100 and FAV-400 animal groups, respectively. Distilled water was administered orally (1 mL) to the HG using the same method. This practice was continued twice a day for 1 week. At the end of the 1st week, the rats were euthanized with a high dose of thiopental anesthesia (50 mg/kg), and their liver tissues were excised. The MDA, tGSH, SOD, and CAT levels in liver tissues were measured. In addition, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined in blood samples taken from the rats before they were euthanized. The liver tissues were assessed biochemically and histopathologically. All experimental results were analyzed by comparing the groups.

Biochemical analyses

Malondialdehyde, glutathione, superoxide dismutase, catalase, and protein determination in tissue

The concentration of SOD, tGSH and MDA in liver tissues of the experimental animals was evaluated using commercially available enzyme-linked immunosorbent assay (ELISA) kits (cat. No. 706002, 703002 and 10009055, respectively) according to the kit instructions (Cayman Chemical Company, Ann Arbor, USA). The determination of CAT was performed according to the method described by Góth.¹⁶ The protein analysis was performed according to the Bradford method.¹⁷

Nuclear factor kappa B and interleukin 6 analysis in tissues

The samples were weighed and all tissues was separated, snap-frozen using liquid nitrogen, and homogenized with a mortar. After the samples were melted, they were stored at 2–8°C as a standard. Phosphate-buffered saline (PBS) (pH 7.4, 1/10 w/v) was added to the samples, which were then vortexed for 10 s and centrifuged for 20 min at 10,000 × g. Nuclear factor kappa B (NF-κB; pg/L) was assayed using a rat NF-κB ELISA immunoassay kit (Shanghai Sunred Biological Technology Co., Ltd., Shanghai, China) and the levels of interleukin 6 (IL-6; ng/L) were assayed using a commercial ELISA kit (Hangzhou Eastbiopharm Co., Ltd., Hangzhou, China).

Alanine aminotransferase and aspartate aminotransferase analysis in tissues

Serum AST and ALT activities were measured with commercially available kits (Roche Diagnostics GmbH, Mannheim, Germany) to assess liver function. Samples were analyzed spectrophotometrically using a cobas® 8000 auto-analyzer (Roche Diagnostics GmbH).

Histopathological analyses

Sections of liver tissue were stained with hematoxylin and eosin (H&E) and examined using an Olympus BX51 fluorescence microscope (Olympus Corp., Tokyo, Japan). Histopathological severity of damage was evaluated as normal (0), mild injury (1), moderate injury (2), or severe injury (3).

Statistical analyses

The experimental results are presented as mean ± standard deviation ($M \pm SD$) and 95% confidence interval (95% CI) of the mean. The Shapiro–Wilk test was used to determine whether the data were distributed normally, and the homogeneity of variances was determined with

the Levene's test. Since the data were normally distributed, one-way analysis of variance (ANOVA) was chosen for statistical analysis. Subsequently, the Tukey's honest significant difference (HSD) and Games–Howell post hoc tests were performed after ANOVA. GraphPad Prism v. 8 software (GraphPad Software, San Diego, USA) was used to create the images. Biochemical findings were analyzed with IBM SPSS v. 25.0 software (IBM Corp., Armonk, USA). A value of $p < 0.05$ was considered statistically significant.

Results

Biochemical findings

Oxidative and antioxidant findings in liver tissue

Favipiravir increased MDA levels more significantly at a dose of 400 mg/kg and decreased tGSH levels more significantly at a dose of 100 mg/kg (Fig. 1). Also, favipiravir decreased SOD and CAT activity more significantly at a dose of 400 mg/kg compared to a dose of 100 mg/kg (Fig. 2).

Nuclear factor kappa B and interleukin 6 findings in liver tissues

We found that levels of NF-κB and IL-6 in liver tissue were significantly increased at a favipiravir dose of 400 mg/kg compared to the 100 mg/kg dose (Fig. 3).

Alanine aminotransferase and aspartate aminotransferase findings in the blood

Favipiravir significantly increased ALT and AST activity in comparison to the HG ($p < 0.001$). The ALT and AST activities were higher in the FAV-400 group than in the FAV-100 group ($p < 0.001$; Fig. 4). Biochemical parameters are presented in Table 1.




Fig. 1. Malondialdehyde (MDA) and total glutathione (tGSH) analysis of liver tissue

HG – healthy group; FAV-100 – favipiravir 100 mg/kg group; FAV-400 – favipiravir 400 mg/kg group. Mean values and 95% confidence intervals (95% CIs) are presented.




Fig. 2. Superoxide dismutase (SOD) and catalase (CAT) analysis of liver tissue

HG – healthy group; FAV-100 – favipiravir 100 mg/kg group; FAV-400 – favipiravir 400 mg/kg group. Mean values and 95% confidence intervals (95% CIs) are presented.




Fig. 3. Nuclear factor kappa-B (NF-κB) and interleukin 6 (IL-6) analysis of liver tissue

HG – healthy group; FAV-100 – favipiravir 100 mg/kg group; FAV-400 – favipiravir 400 mg/kg group. Mean values and 95% confidence intervals (95% CIs) are presented.




Fig. 4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) analysis of blood

HG – healthy group; FAV-100 – favipiravir 100 mg/kg group; FAV-400 – favipiravir 400 mg/kg group. Mean values and 95% confidence intervals (95% CIs) are presented.

Histopathological findings

As shown in Fig. 5A, no microscopic pathological findings were found in the HG. However, moderate edema and lymphocyte infiltration were found in the FAV-100 group (Fig. 5B). Moreover, severe edema, lymphocyte infiltration and hydropic degeneration were observed in the FAV-400 group (Fig. 5C).

Discussion

Favipiravir has been used at high doses for the treatment of COVID-19 as its antiviral efficacy is known to be greater at such doses.¹⁸ In this study, the effects of low and high doses of favipiravir on the liver were analyzed biochemically and histopathologically. The biochemical tests revealed that a high dose of favipiravir significantly increased MDA, NF-κB, IL-6, ALT, and AST levels when compared to the low dose. A high dose also decreased the levels of antioxidants,

Table 1. Results and analysis of biochemical parameters

Variables			MDA [μmol/g protein]	tGSH [nmol/g protein]	SOD [U/g protein]	CAT [U/g protein]	NF-κB [pg/L]	IL-6 [ng/L]	ALT [U/L]	AST [U/L]
Groups (M ±SD)	HG		2.08 ±0.05	5.73 ±0.42	7.58 ±0.06	8.18 ±0.05	2.40 ±0.05	2.19 ±0.06	31.83 ±1.66	34.17 ±1.01
	FAV-100		3.75 ±0.08	3.80 ±0.03	5.58 ±0.04	6.17 ±0.04	3.90 ±0.03	3.84 ±0.02	60.67 ±1.52	65.00 ±1.98
	FAV-400		5.04 ±0.11	2.26 ±0.04	3.48 ±0.04	4.34 ±0.06	5.31 ±0.05	5.01 ±0.09	112.33 ±2.67	128.83 ±3.81
95% CI for the mean change	HG	lower	1.9456	5.6264	7.4242	8.0537	2.2832	2.0269	27.5619	31.5606
		upper	2.2211	5.8403	7.7358	8.3029	2.5201	2.3431	36.1048	36.7727
	FAV-100	lower	3.5322	3.7285	5.4740	6.0701	3.8342	3.7914	56.7588	59.9019
		upper	3.9645	3.8715	5.6860	6.2632	3.9625	3.8920	64.5746	70.0981
	FAV-400	lower	4.7629	2.1667	3.3836	4.1804	5.1779	4.7821	105.4784	119.0467
		upper	5.3105	3.3466	3.5697	4.4896	5.4321	5.2432	119.1882	138.6199
p-values	HG vs. FAV-100		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
	HG vs. FAV-400		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
	FAV-100 vs. FAV-400		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
F value			309.002	2441.326	1889.563	1502.463	1218.373	492.657	409.619	359.465
df (df1/df2)			2/15	2/15	2/15	2/15	2/15	2/15	2/15	2/15

HG – healthy group; FAV-100 – 100 mg/kg favipiravir group; FAV-400 – 400 mg/kg favipiravir group; MDA – malondialdehyde; tGSH – total glutathione; SOD – superoxide dismutase; CAT – catalase; NF-κB – nuclear factor kappa B; IL-6 – interleukin 6; ALT – alanine aminotransferase; AST – aspartate aminotransferase; M ±SD – mean ± standard deviation. The Tukey's honest significant difference and the Games–Howell post hoc tests were performed following analysis of variance (ANOVA) (F (2,15)).




Fig. 5. A. Liver tissue of a healthy rat. No microscopic pathological changes were found in the liver tissue of the animals in the healthy group (HG); B. Liver tissue of the favipiravir 100 mg/kg (FAV-100) group. Moderate-level edema and lymphocyte infiltration were observed in the liver tissue of the FAV-100 group; C. Liver tissue of the favipiravir 400 mg/kg (FAV-400) group. Severe edema, lymphocyte infiltration and hydropic degeneration were observed in the liver tissue of the FAV-400 group

including tGSH, SOD and CAT. The MDA is known to be one of the most important indicators of oxidative damage and is the final product of lipid peroxidation (LPO),¹⁹ a process that is associated with tissue damage.²⁰

In healthy tissues, a small portion of oxygen is converted to reactive oxygen species (ROS) during metabolism in the mitochondria and other cellular compartments. The primary ROS include hydrogen peroxide (H₂O₂),

superoxide radical ($O_2^{\cdot-}$) and hydroxyl radical ($OH\cdot$).¹⁹ Excessive ROS formation causes inflammatory diseases,²¹ oxidative stress, and damage at a molecular and cellular level.²² Results of this study, as well as information derived from other studies, indicate that favipiravir causes oxidative damage at low and high doses. Indeed, recent study showed that favipiravir caused oxidative damage by increasing MDA levels in liver tissue.¹⁵ Another study demonstrated that side effects increased as the dose of favipiravir increased, which is in agreement with our biochemical findings.¹⁰

Antioxidants are known to protect liver tissue from oxidative damage.²³ Therefore, we performed antioxidant measurements to analyze liver injury. The tGSH levels in the liver tissue of animals treated with a 400 mg/kg dose of favipiravir were found to be significantly lower than in those treated with a 100 mg/kg dose. The GSH is a tripeptide that includes L-glutamate, L-cysteine and glycine, and it is one of the most remarkable antioxidants.²⁴ Indeed, in living tissues, GSH detoxifies ROS reactions and protects cells from ROS toxicity.²⁵ The decrease in tGSH levels in the liver tissue of animals administered favipiravir indicated that the oxidant/antioxidant balance had changed in favor of oxidants, which was determined to be oxidative stress.²⁶ Similar results were found in another study, in which it was observed that the GSH levels of cells decreased after favipiravir treatment.²⁷

Other parameters used to evaluate oxidative stress included SOD and CAT levels.²⁸ Normal levels of SOD and CAT help maintain tissue integrity and function by neutralizing overproduced ROS.²⁹ Our experimental results showed a decrease in the levels of the enzymatic antioxidants SOD and CAT in groups treated with favipiravir. Similarly, Kara et al. showed that SOD and CAT levels decreased in lung and liver tissue groups treated with favipiravir compared to healthy tissues,¹⁵ which is consistent with our experimental results.

The levels of the pro-inflammatory cytokines NF- κ B and IL-6 were found to be increased in the liver tissue of animals treated with favipiravir. The NF- κ B plays an important role in mediating the cellular response to damage, stress and inflammation.³⁰ According to previous studies, favipiravir increased NF- κ B and IL-6 levels in the liver,¹⁵ and increased NF- κ B in primary intervertebral disc tissue cell cultures.³¹ At the same time, Zhao et al. also reported that favipiravir increased levels of IL-6.³² In other words, favipiravir plays an important role in inflammation by causing an increase in pro-inflammatory cytokine production.

Increased serum transaminase, an important indicator of hepatocellular damage, occurs in 8% of the population.³³ In this study, favipiravir significantly increased ALT and AST levels at a dose of 100 mg/kg and 400 mg/kg. Bayram et al. found that serum ALT and AST levels were elevated in patients treated with favipiravir.³⁴ Another study showed that ALT and AST levels increased in patients

administered favipiravir for the treatment of COVID-19, which caused hepatotoxicity.¹³ Furthermore, a study by Izci Cetinkaya et al. showed a significant increase in ALT and AST levels in patients treated with favipiravir.³⁵

The biochemical results obtained from the liver tissues of animals in this study aligned with the histopathological findings. Severe edema (grade 3), lymphocyte infiltration and hydropic degeneration were observed in the liver tissues of the FAV-400 group, which also had high oxidant and low antioxidant levels. However, only moderate edema (grade 2) and lymphocyte infiltration were observed in the FAV-100 group. These results indicate that increasing the dose of favipiravir increased hepatic edema, lymphocyte infiltration and hydropic degeneration. It has been reported that hydropic degeneration is associated with oxidative liver injury.³⁶ In addition, it was shown that increased inflammatory cells and pro-inflammatory mediators were associated with ROS production.³⁷











Limitations

The study did not investigate the effects of favipiravir in combination with other drugs in the treatment of COVID-19 or other infections. This should be clarified in future studies. Due to a very small sample size used, it is impossible to reliably verify the statistical test assumptions; therefore, the calculated p-values need to be interpreted with caution.

Conclusions

In conclusion, high dose of favipiravir caused significantly more oxidative and inflammatory injury in liver tissue compared to the low dose. Indeed, animals administered a high dose (400 mg/kg) of favipiravir had higher levels of oxidants and pro-inflammatory cytokines, as well as hydropic degeneration of the liver. This is the first study to show hydropic degeneration of the liver with the use of favipiravir. Therefore, hydropic degeneration may be associated with the excessive production of oxidants and pro-inflammatory cytokines. Due to its adverse effects on the liver, close and frequent follow-up of liver bioparameters during favipiravir therapy would be beneficial for predicting the occurrence of complications.

ORCID iDs

Sami Bilici  <https://orcid.org/0000-0003-1076-1447>
Durdur Altuner  <https://orcid.org/0000-0002-5756-3459>
Zeynep Suleyman  <https://orcid.org/0000-0003-0128-7990>
Seval Bulut  <https://orcid.org/0000-0003-4992-1241>
Cengiz Sarigul  <https://orcid.org/0000-0001-8826-5502>
Mine Gulaboglu  <https://orcid.org/0000-0002-3248-1502>
Fikret Altindag  <https://orcid.org/0000-0002-7085-623X>
Adalet Ozcicek  <https://orcid.org/0000-0003-3029-4524>
Cebrail Gursul  <https://orcid.org/0000-0001-6521-6169>
Halis Suleyman  <https://orcid.org/0000-0002-9239-4099>

References

- Drugs and Lactation Database (LactMed). Favipiravir. CAS:259793-96-9. 2022. <https://www.ncbi.nlm.nih.gov/books/NBK556878/>. Accessed September 21, 2022.
- García-Lledó A, Gómez-Pavón J, González del Castillo J, et al. Pharmacological treatment of COVID-19: An opinion paper. *Rev Esp Quimioter.* 2022;35(2):115–130. doi:10.37201/req/158.2021
- Smyk JM, Majewska A. Favipiravir in the battle with respiratory viruses. *Mini Rev Med Chem.* 2022;22(17):2224–2236. doi:10.2174/1389557522666220218122744
- Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smees DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. *Antiviral Res.* 2013;100(2):446–454. doi:10.1016/j.antiviral.2013.09.015
- Batiha GES, Moubarak M, Shaheen HM, et al. Favipiravir in SARS-CoV-2 infection: Is it worth it? *Comb Chem High Throughput Screen.* 2022;25(14):2413–2428. doi:10.2174/1386207325666220414111840
- Łagocka R, Dziedzic V, Kłos P, Pawlik A. Favipiravir in therapy of viral infections. *J Clin Med.* 2021;10(2):273. doi:10.3390/jcm10020273
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19: Final report. *N Engl J Med.* 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
- Mentré F, Taburet AM, Guedj J, et al. Dose regimen of favipiravir for Ebola virus disease. *Lancet Infect Dis.* 2015;15(2):150–151. doi:10.1016/S1473-3099(14)71047-3
- Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea. *PLoS Med.* 2016;13(3):e1001967. doi:10.1371/journal.pmed.1001967
- Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir: A potential treatment in the COVID-19 pandemic? *J Virus Erad.* 2020;6(2):45–51. doi:10.1016/S2055-6640(20)30016-9
- Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: A prospective, multicenter, open-label, randomized controlled clinical trial. *Front Pharmacol.* 2021;12:683296. doi:10.3389/fphar.2021.683296
- Dogan E, Alkan-Çeviker S, Vurucu S, et al. Investigation of the frequency of adverse effects in patients treated with favipiravir as SARS-CoV-2 treatment. *Klinik Derg.* 2021;34(2):95–98. doi:10.36519/kd.2021.3563
- Kumar P, Kulkarni A, Sharma M, Rao PN, Reddy DN. Favipiravir-induced liver injury in patients with coronavirus disease 2019. *J Clin Transl Hepatol.* 2021;9(2):276–278. doi:10.14218/JCTH.2021.00011
- Japanese Ministry of Health, Labour and Welfare. Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. Handling of marketing application for combination products. October 24, 2014. <https://www.pmda.go.jp/files/000153158.pdf>. Accessed October 10, 2021.
- Kara A, Yakut S, Caglayan C, Atçali T, Ulucan A, Kandemir FM. Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: Biochemical and histopathological approach [published online as ahead of print on April 21, 2022]. *Drug Chem Toxicol.* 2022. doi:10.1080/01480545.2022.2066116
- Góth L. A simple method for determination of serum catalase activity and revision of reference range. *Clin Chim Acta.* 1991;196(2–3):143–151. doi:10.1016/0009-8981(91)90067-M
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976;72(1–2):248–254. doi:10.1016/0003-2697(76)90527-3
- Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. Addendum: The efficacy and safety of favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials. *Sci Rep.* 2022;12(1):1996. doi:10.1038/s41598-022-05835-2
- Özcan O, Erdal H, Çakırca G, Yönden Z. Oxidative stress and its impacts on intracellular lipids, proteins and DNA [in Turkish]. *J Clin Exp Invest.* 2015;6(3):383–389. doi:10.5799/ahinjs.01.2015.03.0545
- Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: Mechanisms, inhibition, and biological effects. *Biochem Biophys Res Commun.* 2005;338(1):668–676. doi:10.1016/j.bbrc.2005.08.072
- Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014;20(7):1126–1167. doi:10.1089/ars.2012.5149
- Jakubczyk K, Dec K, Kałduńska J, Kawczuga D, Kochman J, Janda K. Reactive oxygen species: Sources, functions, oxidative damage. *Pol Merkuri Lek.* 2020;48(284):124–127. PMID:32352946.
- Poli G, Albano E, Dianzani MU. The role of lipid peroxidation in liver damage. *Chem Phys Lipids.* 1987;45(2–4):117–142. doi:10.1016/0009-3084(87)90063-6
- Kurt N, Gunes O, Suleyman B, Bakan N. The effect of taxifolin on high-dose-cisplatin-induced oxidative liver injury in rats. *Adv Clin Exp Med.* 2021;30(10):1025–1030. doi:10.17219/acem/138318
- Owen JB, Butterfield DA. Measurement of oxidized/reduced glutathione ratio. *Methods Mol Biol.* 2010;648:269–277. doi:10.1007/978-1-60761-756-3_18
- Kisaoglu A, Borekci B, Yapca OE, Bilen H, Suleyman H. Tissue damage and oxidant/antioxidant balance. *Eurasian J Med.* 2013;45(1):47–49. doi:10.5152/eajm.2013.08
- Gunaydin-Akyildiz A, Aksoy N, Boran T, İlhan EN, Özhan G. Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells. *Toxicol Lett.* 2022;371:9–16. doi:10.1016/j.toxlet.2022.09.011
- Ji Y, Gao Y, Chen H, Yin Y, Zhang W. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. *Nutrients.* 2019;11(9):2062. doi:10.3390/nu11092062
- Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. *Toxicology.* 2003;189(1–2):41–54. doi:10.1016/S0300-483X(03)00151-3
- Zhongyi S, Sai Z, Chao L, Jiwei T. Effects of nuclear factor kappa B signaling pathway in human intervertebral disc degeneration. *Spine (Phila Pa 1976).* 2015;40(4):224–232. doi:10.1097/BRS.0000000000000733
- Yılmaz I, Akalan H, Sirin Yasar D, Karaarslan N, Özbek H, Ates O. Is favipiravir a potential therapeutic agent in the treatment of intervertebral disc degeneration by suppressing autophagy and apoptosis? *Turk Neurosurg.* 2022;32(4):680–687. doi:10.5137/1019-5149.JTN.38252-22.3
- Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. *Biomed Pharmacother.* 2021;133:110825. doi:10.1016/j.biopha.2020.110825
- Lala V, Goyal A, Bansal P, Minter D. Liver function tests. In: *StatPearls*. Treasure Island, USA: StatPearls Publishing; 2021. <https://www.ncbi.nlm.nih.gov/books/NBK482489/>
- Bayram M, Yildirim O, Özmen RS, et al. Elevation of serum transaminase levels due to favipiravir use in the treatment of COVID-19. *Cureus.* 2021;13(9):e18166. doi:10.7759/cureus.18166
- Izci Cetinkaya F, Karagoz H, Yildiz O. Comparison of liver safety of favipiravir and hydroxychloroquine in COVID-19 treatment. *Klinik Dergisi.* 2020;33(3):235–240. doi:10.5152/kd.2020.49
- Farzanegi P, Dana A, Ebrahimipour Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. *Eur J Sport Sci.* 2019;19(7):994–1003. doi:10.1080/17461391.2019.1571114
- Gursul C, Özcicek A, Ozkaraca M, et al. Amelioration of oxidative damage parameters by carvedilol on methanol-induced liver injury in rats. *Exp Anim.* 2022;71(2):224–230. doi:10.1538/expanim.21-0143